Phase 2 N=11 Recombinant Human Prolactin for Lactation Induction
Lactation
Primary: Change in Breast Milk Volume Baseline to 7 Days — -12; 429; 44 % change from baseline
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=6 Recombinant Human Prolactin for Lactation Induction
Lactation
Primary: Breast Milk Production — 66.1 mL/day
N/A N=22 Impact of Vitamin D Supplementation on Lactation Associated Bone Loss
Osteoporosis
Primary: Change in Bone Mineral Density (BMD) in HIP at 6 Months — -0.041; 0.011 grams/cm^2
Phase 2 N=21 The Safety and Efficacy of Recombinant Human Prolactin
Healthy
Primary: Galactorrhea — 0; 56 percentage of participants
N/A N=180 Early Initiation of Milk Expression in Mothers of Very Low Birth Weight Infants
Breast Milk Expression
Primary: Pumped Milk Volume Day 1 — 3; 4; 5 mL — p=0.015
N/A N=31 Breastfeeding and Exercise for Healthy Infants and Postpartum Moms Too!
Osteoporosis · Obesity · Weight Loss
Primary: Bone Mineral Density-Total Body — -0.3; -1.1 percent change in BMD (g/cm2) — p=<0.05
Phase 1 N=5 Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
Vulvovaginal Candidiasis · Candida Infection · Vaginal Candidiasis
Primary: SCY-078 Breast Milk Concentrations. — 0; 37.64; 72.22; 43.85 ng/mL
Phase 4 N=35 Postpartum Levonorgestrel-releasing Intrauterine System and Breastfeeding
Postpartum Contraception
Primary: Breastfeeding — 10; 9 participants
N/A N=74 Prenatal Breast Pump Education of Mothers and Their Support Person
Preterm Birth · Breast Feeding
Primary: Onset of Lactogenesis Stage II Through Volume Attainment — 84.8; 81 hours — p=0.985
Phase 2 N=69 Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss
Lactation Suppressed
Primary: Number of Participants Reporting Breast Pain — 16; 30 Participants
Phase 2 N=73 Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss
Lactation Suppressed
Primary: Number of Participants Reporting Breast Pain — 10; 32 Participants
N/A N=52 Milk in Life Conditions (MiLC): Bacterial Composition of Human Milk Pumped and Stored in "Real-Life" Conditions
Human Milk Microbiome · Bacterial Growth
Primary: Bacterial Community Richness — 64.2; 58.9; 64.0; 60.8 Observed taxa — p=0.9
Phase 3 N=95 Labor and Delivery Implant Insertion: A Randomized Controlled Trial
Postpartum Contraception · Family Planning
Primary: Time to Lactogenesis Stage II [Questionnaire] — 65; 67.5 hours
N/A N=124 Newborn Feeding and Infant Phenotype
Breast Feeding
Primary: Change in Total Adipose Tissue Volume — 0.718; 0.901; 0.775 Litres
Phase 4 N=30 Progestin-Only Pill Use and Breastfeeding Study
Contraception · Breastfeeding
Primary: Exclusive Lactation Among Birthing People at 8 Weeks Postpartum. — 7; 7; 6 Participants
Phase 4 N=10 A Study Of Pregabalin (Lyrica) Drug Levels In Urine, Plasma And Breast Milk Of Healthy Lactating Women
Healthy Lactating Women
Primary: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) — 32.50 microgram*hour/milliliter (mcg*hr/mL)
N/A N=40 Global Effects of a Probiotic Strain on Lactating Women
Mastitis
Primary: Evidence of Clinically Definite Mastitis Confirmed by Microbiological Cultures and Somatic Cell Counts — 3.09; 2.90 log10 CFU/mL
N/A N=2,108 The Impact of Telelactation Services on Breastfeeding Outcomes
Breastfeeding
Primary: Breastfeeding Duration 1 — 674; 639 Participants — p=0.08
Phase 2 N=15 Metformin to Augment Low Milk Supply (MALMS) Study
Low Milk Supply · Pre-diabetes · Insulin Resistance
Primary: Peak Change in Milk Output — 8; -58 milliliters
Phase 4 N=16 Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women
Healthy Lactating Women
Primary: Daily Infant Dose — 0.0331; 0.0337; 0.0002 Milligrams per day
Phase 1 N=8 A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women
Healthy Participants
Primary: The Maximum Observed Concentration of Nirmatrelvir in Breast Milk Over the Dosing Interval — 1904 Nanograms / milliliter (ng/mL)
N/A N=3,188 Low-birthweight Infant Feeding Exploration
Low Birthweight · Pre-Term
Primary: Length-for-Age Z-score — -1.43 Z-score
Early Phase 1 N=4 The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women
Ketamine · Lactation
Primary: Ketamine Concentration in Breast Milk, up to 12 Hours at 3 Hour Intervals, Following an IM Administration of .5mg/kg Ketamine — 51.2; 22.6; 10.6; 4.5 ng/mL
Phase 3 N=460 Establishing the Vitamin D Requirements During Lactation
Vitamin D Deficiency
Primary: 25-Hydroxyvitamin D Levels for Postpartum Mother 7 Months After Delivery — 28.5; 38.0; 55.6 ng/mL
N/A N=99 Breastfeeding Support Intervention in Jaundiced Infants
Jaundice · Breastfeeding
Primary: Number of Participants Exclusively Breastfeeding at 3 Months, or 3 Months Corrected if the Infant Was Born Prematurely — 22; 24 Participants — p=0.40
Phase 4 N=285 BLIS - Breastfeeding Levonorgestrel IUD Study
Contraception
Primary: Breastfeeding Continuation Rates at 8 Weeks Postpartum — 88; 86 Participants
N/A N=280 PRenatal Video-Based Education and PostPARtum Effects
Breastfeeding
Primary: Breastfeeding Exclusivity — 67; 84 Participants — p=.1200
Phase 1 N=11 A Study of Tirzepatide (LY3298176) in Healthy Lactating Females
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide in Breastmilk From Zero to Infinity (AUC [0-∞]) — NA nanogram*hours per milliliter…
N/A N=345 The Effect of Neuraxial Analgesia on Maternal Breastfeeding
Pain · Breastfeeding
Primary: Breastfeeding at 6 Weeks Post Delivery — 100; 99; 102; 3 Participants — p=.34
N/A N=243 Prenatal Interventions to Promote Exclusive Breastfeeding
Breastfeeding · Intention · Health Behavior
Primary: Number of Participants Who Intended to Exclusively Breastfeed Post-intervention — 40; 36; 86; 67 Participants